NCT02255227View on ClinicalTrials.gov

Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD

PHASE2TerminatedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

April 13, 2015

Primary Completion Date

August 6, 2019

Study Completion Date

July 6, 2022

Conditions
Infections, PneumococcalBowel Diseases, Inflammatory
Interventions
BIOLOGICAL

Prevenar 13

one dose for arm 1 and 2 doses for arm 2

BIOLOGICAL

Pneumo 23

one dose

Trial Locations (8)

25030

Hôpital Jean Minjoz, Besançon

34295

Hôpital Saint-Eloi, Montpellier

42055

CHU de Saint-Etienne, Saint-Etienne

69310

Centre Hospitalier Lyon Sud, Pierre-Bénite

76031

Hôpital Charles Nicolle, Rouen

Unknown

CHU Amiens-Picardie, Amiens

APHP - Hôpital Cochin, Paris

06202

Hôpital de l'Archet II, Nice

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT02255227 - Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD | Biotech Hunter | Biotech Hunter